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Angioedema associated with angiotensin converting enzyme inhibitors (ACEIs) is due to the accumulation
of bradykinin and its metabolites. Angiotensin receptor blockers (ARBs) produce anti-hypertensive effects
by blocking the angiotensin II AT1 receptor action; hence bradykinin-related side effects are not expected.
However, we notice the occurrence of ARB-induced angioedema as not a very rare side effect. Visceral drug-
induced angioedema has been reported with ACEIs, not with ARBs. This underlying review will help edu-
cate readers on the pathophysiology and recent guidelines pertaining to ACEI- and ARB-induced visceral
angioedema.
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T
he well-acclaimed advantages of angiotensin con-
vertingenzymeinhibitors(ACEIs)andangiotensin
receptor blockers (ARBs) in the management of
multiple medical conditions have made them widely used
drugs globally (1). In 2011, in the United States, there
were 164 million prescriptions of ACEIs and 86 million
prescriptions of ARBs (2). Here, we discuss the life-
story of these two classes of drugs, the underlying patho-
physiology behind drug-induced head, neck, and visceral
angioedema; and highlight certain theories postulated in
current literature. To help us in this venture, we utilized
a case of angiotensin receptor blocker-induced visceral
angioedema (ARBVA) at the University Medical Center
in the setting of prior ACEI-induced visceral angioedema
(ACEIVA) and elucidated the morbidity and diagnostic
difficulties that were encountered.
History of ACEIs and ARBs
The renin-angiotensin-aldosterone system (RAAS) has
a major role in the maintenance of blood pressure.
The series of reactions in the RAAS pathway involving
angiotensinogen,angiotensin I (AngI), andangiotensin II
(Ang II) is depicted in column 1 of Fig. 1. The discoveries
of bradykinin and angiotensin converting enzyme (ACE)
in plasma were stepping-stones in the pursuit for drugs
affecting the RAAS (3). Bradykinin is a product of the
kininkallikreinsystemformedbytheproteolyticcleavage
of plasma-based HMW-kininogen (4). It was discovered
in 1948, when detected in animal plasma after injecting
venom from Bothrops jararaca, the South American pit
viper(5).Later,BrazilianscientistSergioFerreirareported
a bradykinin-potentiating peptide (BPP) present in the
venom of Bothrops jararaca (6).
The emergence of bradykinin physiology gave a novel
insight into various physiologic and pathological phe-
nomena including hypotension and cardiovascular shock
caused by toxins and venoms. Bradykinin is a powerful
vasodilator, increases vascular permeability, and enhances
contraction of non-vascular smooth muscle. Bradykinin
is rapidly neutralized in the circulation and disappears
completely in one single passage through the pulmonary
vasculature. The inactivation of bradykinin and the con-
version of Ang I to Ang II in the lungs were found to
be catalyzed by the same enzyme, ACE (7). In 1970, Ng
and Vane illustrated that this angiotensin conversion is
inhibited by Ferreira’s BPP (8). BPPs are members of a
family of peptides whose potentiating action is linked to
effects of ACE inhibition, and captopril, the first ACEI,
was developed from this class of peptide. Further analysis
of BPPs showed the greatest ACE inhibition potency and
hypotensive effect in vivo (9).
As ACEIs were developed, researchers were studying
direct Ang II receptor antagonism. Saralasin, an Ang II
analogue,wasdeveloped asapotent competitiveinhibitor,
but poor oral bio-availability was a drawback. Thereafter,
in the 1980s, a class of imidazole derivatives was found to
reduce blood pressure in rats. The structural modification
of these compounds looked similar to the Ang II molecule
and came out as the first ARB, losartan (10).
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We describe the case of a 31-year-old African-American
woman with a history of hypertension, hemodialysis-
dependent end-stage renal disease, and a 6-year long
history of recurrent abdominal pain. She presented to
the hospital with another bout of severe abdominal pain,
nausea, vomiting, and diarrhea. She had episodic pain
and tenderness over the epigastrium and right lower
quadrant without guarding or rigidity. She was afebrile
and denied sick contacts. Bowel sounds were hypoactive.
Complete blood count, basic metabolic panel, liver
function tests, lactate, and lipase were unremarkable.
For hypertension, her current regimen included nifedi-
pine, losartan, and clonidine. Review of records indicated
that the onset of symptoms coincided with the initiation
of lisinopril 6 years ago. Previous non-contrast abdom-
inal CTs showed isolated peri-hepatic fluid collection.
Contrast was repeatedly avoided given her dialysis depen-
dent kidney disease because immediate dialysis could
not be planned during the majority of her ER visits.
The diagnosis had remained elusive and her complaints
persisted. After 5 years on lisinopril, she experienced
some dry cough and was transitioned to losartan. The
transition to losartan resulted in resolution of the cough.
However, 12 months into losartan therapy, her abdom-
inal symptoms still persisted. Having reviewed the entire
course of her illness, drug-induced visceral angioedema
was suspected.
Eventually, an abdominal CT scan (Fig. 2) with
contrast was requested with planned hemodialysis. It
revealed small bowel wall edema, a classic ‘target sign’
and peri-hepatic fluid. C1-inhibitor and C4 levels were
Fig. 1. Renin-angiotensin system. Mechanisms behind ARB-
induced angioedema. Flow diagram showing feedback-
induced increase in Angiotesin II levels and subsequent ACE
self-inhibition. Also shown is an illustration of feedback-
induced AT2 receptor-mediated bradykinin stimulation
associated with ARB administration. ACEIangiotensin
converting enzyme inhibitor; ARBangiotensin receptor
blocker; ATangiotensin.
Fig. 2. Contrast CT ﬁndings of visceral angioedema. (a)
Peri-hepatic ﬂuid accumulation. (b, c) Small bowel wall
edema, Target sign.
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ARB-induced visceral angioedema. Losartan was discon-
tinued and patient’s symptoms resolved. Follow up until
12 months later confirmed sustained relief of her symp-
toms and established the diagnosis of ARB-induced
visceral angioedema (ARBVA). Awareness is key to early
suspicion and diagnosis. Besides prior clinical experience,
an important step in the diagnosis of visceral angioedema
is the prompt use of a contrast-based multi-detector CT
scan (MDCT) (11). Patients with suspected or recurrent
visceral angioedema may also benefit from the effec-
tive use of ultrasound (11). Figure 3 shows an algorithm
followed in the case described above.
Drug-induced head, neck, and visceral
angioedema
The protection offered by ARBs against adverse ef-
fects like angioedema thought to be mediated by kinins
may not be absolute. There is considerable evidence
for ARB-induced angioedema in literature (12, 13).
Fig. 3. Flowchart depicting the algorithmic approach to episodic abdominal pain that was used in the described case.
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and neck angioedema to be lower with telmisartan versus
ramiprilat0.1%versus0.3%,RR0.4(14).AmongstARBs,
losartan had the highest hazard ratio for angioedema
events,consideringthefactthatlosartanisthemostwidely
used ARB (13).
We conducted MEDLINE search for ‘ACE inhibitor
and ARB angioedema’ and ‘visceral angioedema’ and
reviewed the literature. Korniyenko et al. have reported
a case series in which, citations and references indicate
not less than 27 case reports on ACEIVA (15). Having
searched the MEDLINE database, the case described
here may well be the first case of ARB-induced isolated
intestinal angioedema and it has occurred in the setting
of previous ACEIVA. ARBVA is a constellation of symp-
toms and signs in the setting of ARB use as described
in Table 1. Visceral angioedema is rare but also under-
reported and poorly recognized by the physicians. Hence,
the variables determining the susceptibility to visceral
angioedema versus facial angioedema are difficult to
appreciate. There is a well-known female predominance
for ACEIVA and ACEI-induced facial angioedema; how-
ever, the same has been found to be negative with
ARB-induced angioedema (15, 16). The time period
from initial presentation to diagnosis of ACEIVA was
29 years (15).
Pathophysiology of ACEI- and ARB-induced
angioedema
ACEIswerecreated from a class of molecules representing
BPPs; hence, it is not surprising that bradykinin accumu-
lation/potentiation is an adverse effect of ACEI adminis-
tration. According to one study, during an acute episode
of angioedema with ACEIs, bradykinin levels can rise
as high as 12 times normal (17). The mechanism is des-
cribed below: the effects of bradykinin on B1 and B2
receptors are similar including increase in nitric oxide
and prostacyclin leading tovasodilation and hypotension.
The kinin-system substrate, called Kininogen (high mole-
cular weight and low molecular weight Kininogen), is
primarily metabolized by ACE (kininase II), aminopep-
tidase P (APP), and neutral endopeptidase (NEP) and
secondarily by enzymes dipeptidyl peptidase IV (DPPIV)
and kininase I. The primary enzymes usually metabolize
bradykinin into inactive metabolites. When the primary
metabolizing enzyme is inhibited by ACEI drug, bradyki-
nin substrates are available for metabolism by secondary
enzymes alone. However, these secondary enzymes pro-
duce active, rather than inactive, metabolites including
Lys-bradykinin and Des-Arg-bradykinin that function
at both B1 and B2 receptors and this leads to over-
whelming vasodilation (1) (Fig. 4). Defects or deficiencies
in some of these enzymes including APP and DPP IV
have been found in cases that were predisposed to ACEI-
induced facial angioedema (18, 19). To further strengthen
this observation, the use of DPPIV inhibitors for diabetes
mellitus has been associated with risk of ACE-inhibitor-
induced angioedema (18). Information on rise in brady-
kinin level has not documented in case reports on
ACEIVA (15).
ARBs are thought to produce anti-hypertensive effects
via manipulation of the RAAS cycle by directly block-
ing the Ang II AT1 receptor action. Hence, while using
ARBs one would not expect side effects attributed to
ACE inhibition and bradykinin accumulation (20). How-
ever, sufficient data is lacking that ARBs do not cause
bradykinin accumulation. On the contrary, there is evi-
dence from Campbell et al. that bradykinin levels were
elevated in patients on losartan. The decrease in the ratios
of BK-(17)/BK-(19), Ang II/Ang I, and Ang-(17)/Ang
I point out that the high bradykinin levels were the result
of lower metabolism by ACE and NEP. Elevated brady-
kinin levels may represent a class effect of AT1 receptor
blockers that contributes to their therapeutic actions and
may also contribute to the angioedema that may accom-
pany this therapy (21). Based on data from MEDLINE
search, we have consolidated the theories behind ARB
angioedema with background evidence in literature.
Feedback inhibition of ACE
The use of ARBs is thought to cause feedback-induced
increase in angiotensin II levels in plasma (22). This may
result in feedback-related self-inhibition of the rate-limiting
step involving ACE (23). Thus, it is hypothesized that
intrinsic ACE inhibition and bradykinin accumulation
may well be the final pathway leading to ARB-induced
angioedema (Fig. 1). The intrinsic, rather than extrinsic,
suppression of ACE activity and the variable threshold in
different populations may account for the lower intensity
and incidence of this adverse effect of ARBs.
Table 1. Teaching pearls for diagnosis of ARBVA. Angio-
tensin receptor blocker-induced visceral angioedema
Angiotensin receptor blocker-induced visceral angioedema
(ARBVA):
 Abdominal pain with or without nausea, vomiting, and
diarrhea.
 Occurs as acute exacerbations on chronic low-grade pain.
 Symptom onset within days to many years since starting on
an ARB.
 CT abdomen with contrast showing visceral edema.
 Normal C1 esterase inhibitor and C4 level.
 Symptoms resolving with discontinuation of ARB within days
to weeks.
 Absence of alternative diagnoses.
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Another concept that may describe the phenomenon
behind ARB angioedema is that the ARB molecule exerts
a competitive inhibition on the AT1 receptor. Hence, the
feedback-induced increase in plasma levels of angiotensin
II levels may, per se, activate vascular AT2 receptors that
are available and generate bradykinin (22). This, in turn,
may stimulate bradykinin BK2 receptors in the endothe-
lium and causes vasodilation and angioedema (23, 24).
Current practice and guidelines
Authors in the recent past have recommended that phy-
sicians not prescribe ARBs to patients who have had
an episode of angioedema with ACEIs because it can
be life-threatening (15, 24). Recurrent angioedema has
been reported to occur in 1.510% of patients afterchang-
ing from ACEI to ARB. But, it is believed that this
could represent residual effects of ACEI angioedema,
with the majority of cases occurring within a month of
ACEI discontinuation. From more recent meta-analysis
studies, it is recommended that ARBs should be consid-
ered for use in patients with a history of ACE induced
angioedema who have a high therapeutic need for angio-
tensin inhibition as long as the patient is warned about
the risks (2527). The reason is that when compared
to ACEIs, the incidence of ARB-induced angioedema,
besides being relatively low in number, was similar to that
of beta-blockers and placebo (incidence rates of 4.38,
ACEI, ARB and beta-blockers, respectively) (13). After
discontinuing ACEI, waiting for at least 4 weeks before
cautiously starting ARB is recommended, so that residual
ACEI-induced recurrent angioedema is not mistaken as
a new ARB-induced angioedema (28).
In our patient’s case, ideally, an ARB is an important
medication given the history of HTN so as to prevent
or delay cardiovascular morbidity. She is scheduled for
a kidney transplant and it becomes even more beneficial
to have an ARB in her regimen. However, she clearly
had a 12-month long period of symptoms and signs of
ARBVA, and it is unlikely to be a phenomenon that is
comparable to placebo effect. ACE inhibitors are dialyz-
able, and she underwent hemodialysis regularly, indicat-
ing that this is unlikely to be a case of recurrent ACEIVA
aftermonthsofACEIdiscontinuation.Re-challengingher
with an ARB may produce symptoms most likely at some
point of time, which may be lethal if it affects the head
and neck. This has been the fear for many years and
continues to be so amongst many clinicians. The patient
was informed about these recommendations and was not
willing to take the risk of recurrent ARBVA or head and
neck angioedema.
Unlike research in ACEIs, there is scarce knowledge
on biochemical changes in bradykinin and other metabo-
lites with the use of ARBs. Research modalities with bio-
chemical or radio-nuclear evidence in animals or humans
could be utilized. There is a serious need to study the
nature of the feedback regulation of RAA system while
using ARBs and its effect on pulmonary ACE activity,
plasma ACE levels, plasma levels or in vivo activity
of bradykinins, des-Arg-BK, DPP IV, APP and NEP,
kininase 1 and substance P.
Conclusion
Attempts to further understand this phenomenon of
angioedema associated with ARBs may help introduce
novel therapeutic medical therapies and throw light on
Fig. 4. Mechanism of bradykinin accumulation associated with ACEI use. ACE inhibition leads to diversion of substrates
toward secondary enzymes rather than primary metabolizing enzymes thereby producing physiologically active metabolites.
LMWlow molecular weight; HMWhigh molecular weight; B1bradykinin 1; B2bradykinin 2.
Drug-induced visceral angioedema
Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25260 - http://dx.doi.org/10.3402/jchimp.v4.25260 5
(page number not for citation purpose)future guidelines for transitioning patients with a history
of ACEI angioedema from ACEIs to ARBs. The results of
NICE guidelines from the United Kingdom recommend-
ing ACEIs and ARBs as first-line anti-hypertensive for
people under 55 years of age may lead to further increase
in the use of ACEIs and ARBs (29). Clinicians should
be aware that cross-reactivity of angioedema between
ACE inhibitors and ARBs, albeit low, could affect visceral
organs and cause significant morbidity that can be missed
for years. Creating this awareness amongst physicians will
help in avoiding delays in diagnosis, unnecessary testing,
and considerable morbidity. Visceral angioedema should
receive the same level of attention by physicians, as head
and neck angioedema. Care should be taken to avoid pre-
maturely considering such cases with abdominal pain
and hospital readmissions as secondary gain. After all,
the eyes can only see what the mind knows.
Key points
Cross-reactivity of angioedema between angiotensin con-
verting enzyme inhibitors (ACEIs) and ARBs could
affect visceral organs.
Meta-analyses recommend cautious use of ARB after
an episode of ACEI-induced head, neck, and visceral
angioedema after appropriate counseling.
As against current evidence, it could be hypothesized
that bradykinin metabolism may potentially be a driving
factor behind ARB-associated angioedema.
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